keyword
MENU ▼
Read by QxMD icon Read
search

Pancreatic neuroendocrine tumor

keyword
https://www.readbyqxmd.com/read/29352378/can-histogram-analysis-of-mr-images-predict-aggressiveness-in-pancreatic-neuroendocrine-tumors
#1
Riccardo De Robertis, Bogdan Maris, Nicolò Cardobi, Paolo Tinazzi Martini, Stefano Gobbo, Paola Capelli, Silvia Ortolani, Sara Cingarlini, Salvatore Paiella, Luca Landoni, Giovanni Butturini, Paolo Regi, Aldo Scarpa, Giampaolo Tortora, Mirko D'Onofrio
OBJECTIVES: To evaluate MRI derived whole-tumour histogram analysis parameters in predicting pancreatic neuroendocrine neoplasm (panNEN) grade and aggressiveness. METHODS: Pre-operative MR of 42 consecutive patients with panNEN >1 cm were retrospectively analysed. T1-/T2-weighted images and ADC maps were analysed. Histogram-derived parameters were compared to histopathological features using the Mann-Whitney U test. Diagnostic accuracy was assessed by ROC-AUC analysis; sensitivity and specificity were assessed for each histogram parameter...
January 19, 2018: European Radiology
https://www.readbyqxmd.com/read/29351120/grading-using-ki-67-index-and-mitotic-rate-increases-the-prognostic-accuracy-of-pancreatic-neuroendocrine-tumors
#2
Prejesh Philips, David A Kooby, Shishir Maithel, Nipun B Merchant, Sharon M Weber, Emily R Winslow, Syed Ahmad, Hong J Kim, Charles R Scoggins, Kelly M McMasters, Robert C G Martin
OBJECTIVES: To measure the usefulness of Ki-67 proliferative index (Ki-67 index) as a prognostic variable for grading pancreatic neuroendocrine tumors. METHODS: A multi-institutional prospective database comprising 350 patients. Grading based on mitotic activity (<2 mitoses/10 high-power fields, 2-20 and >20) and Ki-67 index (<3% per 10 high-power fields, 3%-20% and >20%). Final grade selected based on higher grade of either variable. RESULTS: Most patients were in the less than 3% (n = 158) and 3% to 20% Ki-67 category (n = 107), with a minority being high-grade (Ki-67 > 20%, n = 27)...
January 18, 2018: Pancreas
https://www.readbyqxmd.com/read/29349562/the-influence-of-elevated-hormone-levels-on-physiologic-accumulation-of-68ga-dotatoc
#3
Masao Watanabe, Yuji Nakamoto, Sho Koyasu, Takayoshi Ishimori, Akihiro Yasoda, Kaori Togashi
OBJECTIVE: PET/CT imaging with 68Ga-1,4,7,10-tetraazacyclododecane-N,N',N″,N‴-tetraacetic acid-D-Phe1-Tyr3-octreotide (DOTATOC) is useful in patients with neuroendocrine tumors (NETs). Functioning NETs by definition secrete abnormal levels of hormones, causing clinical symptoms. It is known that physiologic accumulation can be seen in some organs, but it remains unknown whether elevated hormone levels can affect the physiologic accumulation pattern of 68Ga-DOTATOC. We aimed to investigate the influence of higher hormone levels on physiologic accumulation of 68Ga-DOTATOC...
January 18, 2018: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/29335487/increased-expression-of-glp-1r-in-proliferating-islets-of-men1-mice-is-detectable-by-68ga-ga-do3a-vs-cys40-exendin-4-pet
#4
Azita Monazzam, Joey Lau, Irina Velikyan, Su-Chen Li, Masoud Razmara, Ulrika Rosenström, Olof Eriksson, Britt Skogseid
Multiple endocrine neoplasia type 1 (MEN1) is an endocrine tumor syndrome caused by heterozygous mutations in the MEN1 tumor suppressor gene. The MEN1 pancreas of the adolescent gene carrier frequently contain diffusely spread pre-neoplasias and microadenomas, progressing to macroscopic and potentially malignant pancreatic neuroendocrine tumors (P-NET), which represents the major death cause in MEN1. The unveiling of the molecular mechanism of P-NET which is not currently understood fully to allow the optimization of diagnostics and treatment...
January 15, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29332158/combined-sublethal-irradiation-and-agonist-anti-cd40-enhance-donor-t-cell-accumulation-and-control-of-autochthonous-murine-pancreatic-tumors
#5
Lindsay K Ward-Kavanagh, Kathleen M Kokolus, Timothy K Cooper, Aron E Lukacher, Todd D Schell
Tumor-reactive T lymphocytes can promote the regression of established tumors. However, their efficacy is often limited by immunosuppressive mechanisms that block T cell accumulation or function. ACT provides the opportunity to ameliorate immune suppression prior to transfer of tumor-reactive T cells to improve the therapeutic benefit. We evaluated the combination of lymphodepleting whole body irradiation (WBI) and agonist anti-CD40 (αCD40) antibody on control of established autochthonous murine neuroendocrine pancreatic tumors following the transfer of naïve tumor-specific CD8 T cells...
January 13, 2018: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29331723/progesterone-arrested-cell-cycle-progression-through-progesterone-receptor-isoform-a-in-pancreatic-neuroendocrine-neoplasm
#6
Samaneh Yazdani, Atsuko Kasajima, Yoshiaki Onodera, Keely May McNamara, Kazue Ise, Yasuhiro Nakamura, Tomoyoshi Tachibana, Fuyuhiko Motoi, Michiaki Unno, Hironobu Sasano
In pancreatic neuroendocrine neoplasms (Pan-NEN) progesterone signaling has been shown to have both inhibitory and stimulatory effects on cell proliferation. The ability of progesterone to inhibit tumor proliferation is of particular interest and is suggested to be mediated through the less abundantly expressed progesterone receptor (PR) isoform A (PRA). To date the mechanistic processes underlying this inhibition of proliferation remain unclear. To examine the mechanism of PRA actions, the human Pan-NEN cell line QGP-1, that endogenously expresses PR isoform B (PRB) without PRA, was transfected with PRA...
January 10, 2018: Journal of Steroid Biochemistry and Molecular Biology
https://www.readbyqxmd.com/read/29330294/establishment-of-the-first-well-differentiated-human-pancreatic-neuroendocrine-tumor-model
#7
Daniel Benten, Yasmin Behrang, Ludmilla Unrau, Victoria Weissmann, Gerrit Wolters-Eisfeld, Susanne Burdak-Rothkamm, Felix R Stahl, Martin Anlauf, Patricia Grabowski, Markus Möbs, Jan Dieckhoff, Bence Sipos, Martina Fahl, Corinna Eggers, Daniel Perez, Maximilian Bockhorn, Jakob R Izbicki, Ansgar W Lohse, Joerg Schrader
Clinical options for systemic therapy of neuroendocrine tumors (NET) are limited. Development of new drugs requires suitable representative in vitro and in vivo model systems. So far, the unavailability of a human model with a well-differentiated phenotype and typical growth characteristics has impaired pre-clinical research in NET. Herein, we establish and characterize a lymph node-derived cell line (NT-3) from a male patient with well-differentiated pancreatic NET. Neuroendocrine differentiation and tumor biology was compared to existing NET cell lines BON and QGP-1...
January 12, 2018: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/29325706/contrast-harmonic-eus-for-the-prediction-of-pancreatic-neuroendocrine-tumor-aggressiveness-with-videos
#8
Maxime Palazzo, Bertrand Napoléon, Rodica Gincul, Mathieu Pioche, Bertrand Pujol, Christine Lefort, Fabien Fumex, Vincent Hautefeuille, Monique Fabre, Jérome Cros, Michèle Felce, Anne Couvelard, Alain Sauvanet, Philippe Lévy, Philippe Ruszniewski, Laurent Palazzo
BACKGROUND AND AIM: Contrast-harmonic EUS (CH-EUS) has the ability to depict a tumor microvasculature. Decreased microvascular density has been identified as a factor associated with tumor aggressiveness. We aimed to study the accuracy of CH-EUS for the prediction of pancreatic neuroendocrine tumor (PNET) aggressiveness. METHODS: Between June 2009 and March 2015, all consecutive patients with histology-proven PNETs and CH-EUS examination were included. Nine endosonographers analyzed blindly all the videos...
January 8, 2018: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/29319794/an-observational-analysis-of-insulinoma-from-1-single-institution
#9
Zhixuan Zeng, Shuhong Hu, Shiying Shao
Background: Insulinoma is the commonest functioning pancreatic neuroendocrine tumor causing hyperinsulinemic hypoglycemia. This study is aimed to evaluate the clinical features, preoperative laboratory and imaging diagnosis, and pathologic findings of insulinoma. Methods: Data of the patients from 2001 to 2016 diagnosed as insulinoma in Tongji Hospital, China were retrospectively extracted and analyzed. Results: A total of 40 patients were diagnosed as insulinoma with a male/female ratio of 0...
January 8, 2018: QJM: Monthly Journal of the Association of Physicians
https://www.readbyqxmd.com/read/29316326/orthopedia-homeobox-is-preferentially-expressed-in-typical-carcinoids-of-the-lung
#10
Krisztina Z Hanley, Zachary J Dureau, Cynthia Cohen, Dong M Shin, Taofeek K Owonikoko, Gabriel L Sica
BACKGROUND: Twenty-seven percent of neuroendocrine tumors (NETs) are associated with distant metastases, and in some patients, the primary site is unknown. Orthopedia homeobox protein (OTP) has been described as a useful marker for lung carcinoids (LCs) and for separating low-grade typical carcinoids (TCs) from intermediate-grade atypical carcinoids (ACs) in resection specimens. This study evaluated OTP, thyroid transcription factor 1 (TTF-1), and Ki-67 expression in fine-needle aspiration (FNA) samples of various NETs...
January 9, 2018: Cancer
https://www.readbyqxmd.com/read/29313698/cystic-pancreatic-neuroendocrine-tumor-pancreatic-endocrine-or-neuroendocrine-tumor-endoscopic-ultrasonography
#11
Modesto J Varas, Carme Loras, Agustí Balboa
Cystic pancreatic neuroendocrine tumors (cPNETs) represent less than 8% of all pancreatic cysts and approximately 13% of pancreatic endocrine tumors (PNETs). According to a recent review, the percentage of non-functional (NF) PNETs is 85% and 44.6% are incidentalomas. In our series of 75 PNET cases, ten cPNET cases (13%) were identified which are discussed and summarized below.
January 9, 2018: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/29309781/technical-feasibility-diagnostic-yield-and-safety-of-micro-forceps-biopsies-during-eus-evaluation-of-pancreatic-cystic-lesions-with-video
#12
Chetan Mittal, Joshua C Obuch, Hazem Hammad, Steven A Edmundowicz, Sachin Wani, Raj J Shah, Brian C Brauer, Augustin R Attwell, Jeffrey B Kaplan, Mihir S Wagh
BACKGROUND AND AIMS: Through-the-needle micro forceps are a recent addition to the EUS armamentarium for evaluation of pancreatic cystic lesions (PCLs). The main aim of this study was to assess the technical feasibility, diagnostic yield and safety of EUS-guided micro forceps biopsy for PCLs. METHODS: Our electronic endoscopy database was queried to identify patients who underwent EUS-FNA of PCLs and micro forceps biopsies, during the same procedure. The wall of the cyst was biopsied with the micro forceps through the 19-gauge needle and cyst fluid was collected for cytology, and CEA levels...
January 5, 2018: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/29309705/common-genetic-variants-associated-with-pancreatic-adenocarcinoma-may-also-modify-risk-of-pancreatic-neuroendocrine-neoplasms
#13
Ofure Obazee, Gabriele Capurso, Francesca Tavano, Livia Archibugi, Antonio De Bonis, William Greenhalf, Tim Key, Claudio Pasquali, Anna Caterina Milanetto, Thilo Hackert, Paola Fogar, Valbona Liço, Christos Dervenis, Rita T Lawlor, Luca Landoni, Maria Gazouli, Carlo Federico Zambon, Niccola Funel, Oliver Strobel, Krzysztof Jamroziak, Cinzia Cantù, Ewa Malecka-Panas, Stefano Landi, John P Neoptolemos, Daniela Basso, Renata Talar-Wojnarowska, Maria Rinzivillo, Angelo Andriulli, Federico Canzian, Daniele Campa
Pancreatic neuroendocrine neoplasms (pNEN) account for less than 5% of all pancreatic neoplasms and genetic association studies on susceptibility to the disease are limited. We sought to identify possible overlap of genetic susceptibility loci between pancreatic ductal adenocarcinoma (PDAC) and pNEN; therefore, PDAC susceptibility variants (n=23) from Caucasian genome-wide association studies (GWAS) were genotyped in 369 pNEN cases and 3,277 controls from the PANcreatic Disease ReseArch (PANDoRA) consortium to evaluate the odds associated with pNEN risk, disease onset and tumor characteristics...
December 22, 2017: Carcinogenesis
https://www.readbyqxmd.com/read/29309627/functional-defects-from-endocrine-disease-associated-mutations-in-hlxb9-and-its-interacting-partner-nono
#14
Sampada S Kharade, Vaishali I Parekh, Sunita K Agarwal
The insulin-secreting pancreatic neuroendocrine tumors (PNETs), insulinomas, characterized by increased pancreatic islet β-cell proliferation express the phosphorylated isoform of the β-cell differentiation factor HLXB9 that interacts with NONO/p54NRB, a survival factor. Interestingly, two different homozygous germline mutations in HLXB9, p.F248L and p.F272L, were reported in neonatal diabetes, a condition characterized by inadequate number of functional β-cells. Also, two somatic heterozygous NONO mutations were found in endocrine-related tumors, p...
January 4, 2018: Endocrinology
https://www.readbyqxmd.com/read/29307515/clinical-outcome-and-long-term-survival-of-150%C3%A2-consecutive-patients-with-pancreatic-neuroendocrine-tumors-a-comprehensive-analysis-by-the-world-health-organization-2010-grading-classification
#15
Ben-Yuan Deng, Fei Liu, Si-Neng Yin, An-Ping Chen, Lin Xu, Bo Li
BACKGROUND AND OBJECTIVE: The World Health Organization (WHO) has revised its grading system for pancreatic neuroendocrine tumors (PNETs) in 2010 into three main group, which has not been widely and comprehensively evaluated. We aimed to validate the clinical valve of this system associated with the clinical outcome and long-term survival when applied to PNETs, which were rare and heterogeneous. METHODS: We retrospectively collected and analyzed the data of 150 consecutive patients with PNETs who underwent a resection...
January 4, 2018: Clinics and Research in Hepatology and Gastroenterology
https://www.readbyqxmd.com/read/29305893/randomized-trial-comparing-the-franseen-and-fork-tip-needles-for-eus-guided-fine-needle-biopsy-of-solid-pancreatic-mass-lesions
#16
Ji Young Bang, Shantel Hebert-Magee, Udayakumar Navaneethan, Muhammad K Hasan, Robert Hawes, Shyam Varadarajulu
BACKGROUND AND AIMS: Recently, 3-plane symmetric needle with Franseen geometry and Fork-tip biopsy needle have been developed for histological tissue procurement. We compared 22-gauge Franseen and 22-gauge Fork-tip needles in patients undergoing EUS-guided sampling of pancreatic masses. METHODS: Fifty patients underwent sampling using both 22-gauge Franseen and 22-gauge Fork-tip needles, with randomization of needle order. Two dedicated passes were performed using both needles for cell block...
January 3, 2018: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/29301477/eus-guided-reverse-bevel-fine-needle-biopsy-sampling-and-open-tip-fine-needle-aspiration-in-solid-pancreatic-lesions-a-prospective-comparative-study
#17
Per Hedenström, Akif Demir, Kaveh Khodakaram, Ola Nilsson, Riadh Sadik
OBJECTIVES: Different diagnostic entities can present as solid pancreatic lesions (SPL). This study aimed to explore the utility of endoscopic ultrasound-guided reverse bevel fine-needle biopsy sampling (EUS-FNB) in SPLs. MATERIAL AND METHODS: In 2012-2015, consecutive patients with SPLs were prospectively included in a tertiary center setting and subjected to dual needle sampling with a 22 gauge reverse bevel biopsy needle and a conventional 25 gauge open tip aspiration needle (EUS-FNA)...
January 4, 2018: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/29290942/identification-of-novel-serum-autoantibodies-against-eid3-in-non-functional-pancreatic-neuroendocrine-tumors
#18
Koji Hontani, Takahiro Tsuchikawa, Takaki Hiwasa, Toru Nakamura, Takashi Ueno, Toshihiro Kushibiki, Mizuna Takahashi, Kazuho Inoko, Hironobu Takano, Satoshi Takeuchi, Hirotoshi Dosaka-Akita, Masaki Kuwatani, Naoya Sakamoto, Yutaka Hatanaka, Tomoko Mitsuhashi, Hideaki Shimada, Toshiaki Shichinohe, Satoshi Hirano
Pancreatic neuroendocrine tumors (pNETs) are relatively rare heterogenous tumors, comprising only 1-2% of all pancreatic neoplasms. The majority of pNETs are non-functional tumors (NF-pNETs) that do not produce hormones, and as such, do not cause any hormone-related symptoms. As a result, these tumors are often diagnosed at an advanced stage because patients do not present with specific symptoms. Although tumor markers are used to help diagnosis and predict some types of cancers, chromogranin A, a widely used tumor marker of pNETs, has significant limitations...
December 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/29288277/new-guidelines-for-use-of-endoscopic-ultrasound-for-evaluation-and-risk-stratification-of-pancreatic-cystic-lesions-may-be-too-conservative
#19
Nadav Sahar, Anthony Razzak, Zaheer S Kanji, David L Coy, Richard Kozarek, Andrew S Ross, Michael Gluck, Michael Larsen, Shayan Irani, S Ian Gan
BACKGROUND: The role of EUS in managing asymptomatic pancreatic cystic lesions (PCLs) remains unresolved. We retrospectively evaluated EUS in risk stratification of PCLs when adhering to the most recent AGA guidelines. METHODS: Asymptomatic PCLs that were evaluated by EUS from January 2014 to December 2014 were retrospectively reviewed including associated cytology, fluid analysis, and relevant surgical pathology. Cross-sectional imaging reports were reviewed blindly by an expert radiologist using AGA risk stratification terminology...
December 29, 2017: Surgical Endoscopy
https://www.readbyqxmd.com/read/29284590/peptide-receptor-radionuclide-therapy-as-neoadjuvant-therapy-for-resectable-or-potentially-resectable-pancreatic-neuroendocrine-neoplasms
#20
Stefano Partelli, Emilio Bertani, Mirco Bartolomei, Carolina Perali, Francesca Muffatti, Chiara Maria Grana, Marco Schiavo Lena, Claudio Doglioni, Stefano Crippa, Nicola Fazio, Giuseppe Zamboni, Massimo Falconi
BACKGROUND: Peptide receptor radionuclide therapy is a valid therapeutic option for pancreatic neuroendocrine neoplasms. The aim of this study was to describe an initial experience with the use of peptide receptor radionuclide therapy as a neoadjuvant agent for resectable or potentially resectable pancreatic neuroendocrine neoplasms. METHODS: The postoperative outcomes of 23 patients with resectable or potentially resectable pancreatic neuroendocrine neoplasms at high risk of recurrence who underwent neoadjuvant peptide receptor radionuclide therapy (peptide receptor radionuclide therapy group) were compared with 23 patients who underwent upfront surgical operation (upfront surgery group)...
December 25, 2017: Surgery
keyword
keyword
7197
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"